Ourofino - Public Comps and Valuation Multiples

Ourofino Overview

About Ourofino

Ourofino SA is engaged in research, development, production and sales of medicines, vaccines and other veterinary products. The company's reportable segments are Production animals, Companion animals, and International operations. It generates maximum revenue from the Production animals segment. The product portfolio includes Anticoccidials, Antimastitics, Biological, Ectoparasiticides, Endectocides, and others.

Founded

2014

HQ

Employees

1.1K+

Website

ourofino.com

Sectors

Drug Development & Therapeutics
Vaccines & Immunotherapies
BioTech

Financials

LTM Revenue $205M

LTM EBITDA $40.2M

EV

$271M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Ourofino Financials

As of August 2025, Ourofino reported last 12-month revenue of $205M and EBITDA of $40.2M.

In the same period, Ourofino achieved $22.8M in LTM net income.

See Ourofino valuation multiples based on analyst estimates

Ourofino P&L

In the most recent fiscal year, Ourofino reported revenue of $189M and EBITDA of $45.4M.

Ourofino expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Ourofino valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$205M	XXX	$189M	XXX	XXX	XXX
Gross Profit	n/a	XXX	$95.5M	XXX	XXX	XXX
Gross Margin	n/a	XXX	51%	XXX	XXX	XXX
EBITDA	$40.2M	XXX	$45.4M	XXX	XXX	XXX
EBITDA Margin	20%	XXX	24%	XXX	XXX	XXX
EBIT	$32.8M	XXX	$35.6M	XXX	XXX	XXX
EBIT Margin	16%	XXX	19%	XXX	XXX	XXX
Net Profit	$22.8M	XXX	$24.8M	XXX	XXX	XXX
Net Margin	11%	XXX	13%	XXX	XXX	XXX
Net Debt	XXX	XXX	$23.1M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Ourofino including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $205M. EBITDA for the last twelve months was $40.2M. In the most recent fiscal year, Ourofino achieved $189M in revenue and $45.4M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$205M	Analyst estimates available to subscribers	$189M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	$95.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	50.5% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$40.2M	Analyst estimates available to subscribers	$45.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	19.6% EBITDA margin	Analyst estimates available to subscribers	24.0% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$32.8M	Analyst estimates available to subscribers	$35.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	16.0% EBIT margin	Analyst estimates available to subscribers	18.8% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$22.8M	Analyst estimates available to subscribers	$24.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	11.1% net profit margin	Analyst estimates available to subscribers	13.1% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$23.1M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Ourofino

This financial data table provides comprehensive performance metrics for Ourofino, a company based in Brazil. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Ourofino generated $205M in revenue over the last twelve months.
The company achieved $40.2M in EBITDA over the last twelve months.
Net income over the last twelve months reached $22.8M.

Fiscal Year Performance

In the most recent fiscal year, Ourofino reported $189M in total revenue.
Fiscal year EBITDA was $45.4M.
The company maintained a gross profit margin of 50.5% in the most recent fiscal year.
EBITDA margin for the fiscal year was 24.0%.
Net profit margin reached 13.1% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Ourofino. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Ourofino Stock Performance

Ourofino has current market cap of BRL 1.2B (or $220M), and EV of BRL 1.5B (or $271M).

Market Cap Evolution

Ourofino Stock Data

As of September 12, 2025, Ourofino's stock price is BRL 22 (or $4).

See Ourofino trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$271M	$220M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Ourofino Valuation Multiples

Ourofino's trades at 1.4x EV/Revenue multiple, and 6.0x EV/EBITDA.

See valuation multiples for Ourofino and 15K+ public comps

Ourofino Financial Valuation Multiples

As of September 12, 2025, Ourofino has market cap of $220M and EV of $271M.

Equity research analysts estimate Ourofino's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Ourofino has a P/E ratio of 9.7x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$220M	XXX	$220M	XXX	XXX	XXX
EV (current)	$271M	XXX	$271M	XXX	XXX	XXX
EV/Revenue	1.3x	XXX	1.4x	XXX	XXX	XXX
EV/EBITDA	6.7x	XXX	6.0x	XXX	XXX	XXX
EV/EBIT	8.2x	XXX	7.6x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	9.7x	XXX	8.9x	XXX	XXX	XXX
EV/FCF	20.7x	XXX	50.2x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Ourofino Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Ourofino Margins & Growth Rates

Ourofino's last 12 month revenue growth is 6%

Ourofino's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Ourofino's rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Ourofino's rule of X is 36% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Ourofino and other 15K+ public comps

Ourofino Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	6%	XXX	8%	XXX	XXX	XXX
EBITDA Margin	20%	XXX	24%	XXX	XXX	XXX
EBITDA Growth	2%	XXX	30%	XXX	XXX	XXX
Rule of 40	20%	XXX	30%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	36%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	6%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	5%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	32%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial